How Is the Changing Diagnostics Market Impacting POCT?
Lawrence Worden and Robert Lacroix sat down to discuss how diagnostics is shifting from an infrastructure support function to an integrated clinical decision tool for patient care. That shift comes with unique considerations for commercialization and reimbursement.
In the current landscape, FDA approval is just a starting point. Many new point-of-care tests are launched as cash-pay before generating enough evidence for payer coverage, making it critical to demonstrate value to patients directly.
At the same time, functional tests and at-home diagnostics are also becoming more prevalent, a trend that’s reflected in some of the largest diagnostics deals in recent years.
This discussion is a great primer for the point-of-care program at the Next Generation Dx Summit on August 24-25, where Larry and Rob will expand on these topics.